Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California. more
Time Frame | CRVS | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.86% | -3.39% | 0.2% |
1-Month Return | -11.39% | -1.92% | 2.72% |
3-Month Return | 34.36% | -10.54% | 7.31% |
6-Month Return | 282.9% | -4.47% | 10.44% |
1-Year Return | 379.87% | 4.06% | 27.53% |
3-Year Return | 170.7% | 0.94% | 30.88% |
5-Year Return | 82.02% | 36.67% | 89.21% |
10-Year Return | -48.14% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 743.00K | 632.00K | 460.00K | 367.00K | 151.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":85.06,"profit":true},{"date":"2021-12-31","value":61.91,"profit":true},{"date":"2022-12-31","value":49.39,"profit":true},{"date":"2023-12-31","value":20.32,"profit":true}] |
Gross Profit | (743.00K) | (632.00K) | (460.00K) | (367.00K) | (151.00K) | [{"date":"2019-12-31","value":-74300000,"profit":false},{"date":"2020-12-31","value":-63200000,"profit":false},{"date":"2021-12-31","value":-46000000,"profit":false},{"date":"2022-12-31","value":-36700000,"profit":false},{"date":"2023-12-31","value":-15100000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 48.85M | 43.76M | 38.63M | 32.56M | 23.41M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":89.57,"profit":true},{"date":"2021-12-31","value":79.07,"profit":true},{"date":"2022-12-31","value":66.66,"profit":true},{"date":"2023-12-31","value":47.91,"profit":true}] |
Operating Income | (48.85M) | (43.76M) | (38.63M) | (32.56M) | (23.33M) | [{"date":"2019-12-31","value":-4885400000,"profit":false},{"date":"2020-12-31","value":-4376000000,"profit":false},{"date":"2021-12-31","value":-3863000000,"profit":false},{"date":"2022-12-31","value":-3256500000,"profit":false},{"date":"2023-12-31","value":-2332900000,"profit":false}] |
Total Non-Operating Income/Expense | 4.36M | 38.30M | (4.63M) | (8.09M) | (2.18M) | [{"date":"2019-12-31","value":11.39,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-12.08,"profit":false},{"date":"2022-12-31","value":-21.11,"profit":false},{"date":"2023-12-31","value":-5.69,"profit":false}] |
Pre-Tax Income | (46.67M) | (6.00M) | (43.24M) | (41.31M) | (27.03M) | [{"date":"2019-12-31","value":-4667200000,"profit":false},{"date":"2020-12-31","value":-599500000,"profit":false},{"date":"2021-12-31","value":-4324100000,"profit":false},{"date":"2022-12-31","value":-4130700000,"profit":false},{"date":"2023-12-31","value":-2702900000,"profit":false}] |
Income Taxes | (2.92M) | (1.17M) | (5.04M) | 8.74M | - | [{"date":"2019-12-31","value":-33.46,"profit":false},{"date":"2020-12-31","value":-13.41,"profit":false},{"date":"2021-12-31","value":-57.66,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (43.75M) | (4.82M) | (38.20M) | (50.05M) | - | [{"date":"2019-12-31","value":-4374700000,"profit":false},{"date":"2020-12-31","value":-482300000,"profit":false},{"date":"2021-12-31","value":-3820000000,"profit":false},{"date":"2022-12-31","value":-5004900000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (46.67M) | (6.00M) | (43.24M) | (41.31M) | (30.19M) | [{"date":"2019-12-31","value":-4667200000,"profit":false},{"date":"2020-12-31","value":-599500000,"profit":false},{"date":"2021-12-31","value":-4324100000,"profit":false},{"date":"2022-12-31","value":-4130700000,"profit":false},{"date":"2023-12-31","value":-3019200000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (43.75M) | (4.82M) | (38.20M) | (50.05M) | (27.03M) | [{"date":"2019-12-31","value":-4374700000,"profit":false},{"date":"2020-12-31","value":-482300000,"profit":false},{"date":"2021-12-31","value":-3820000000,"profit":false},{"date":"2022-12-31","value":-5004900000,"profit":false},{"date":"2023-12-31","value":-2702900000,"profit":false}] |
EPS (Diluted) | (1.59) | (1.46) | (1.06) | (0.89) | (0.57) | [{"date":"2019-12-31","value":-159,"profit":false},{"date":"2020-12-31","value":-146,"profit":false},{"date":"2021-12-31","value":-106,"profit":false},{"date":"2022-12-31","value":-89,"profit":false},{"date":"2023-12-31","value":-57,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CRVS | |
---|---|
Cash Ratio | 0.90 |
Current Ratio | 0.92 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CRVS | |
---|---|
ROA (LTM) | -23.83% |
ROE (LTM) | -44.91% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CRVS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.79 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.21 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CRVS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 35.73 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.36 |
PEG | NM |
Corvus Pharmaceuticals Inc (CRVS) share price today is $3.848
Yes, Indians can buy shares of Corvus Pharmaceuticals Inc (CRVS) on Vested. To buy Corvus Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CRVS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Corvus Pharmaceuticals Inc (CRVS) via the Vested app. You can start investing in Corvus Pharmaceuticals Inc (CRVS) with a minimum investment of $1.
You can invest in shares of Corvus Pharmaceuticals Inc (CRVS) via Vested in three simple steps:
The 52-week high price of Corvus Pharmaceuticals Inc (CRVS) is $10. The 52-week low price of Corvus Pharmaceuticals Inc (CRVS) is $1.3.
The price-to-earnings (P/E) ratio of Corvus Pharmaceuticals Inc (CRVS) is
The price-to-book (P/B) ratio of Corvus Pharmaceuticals Inc (CRVS) is 35.73
The dividend yield of Corvus Pharmaceuticals Inc (CRVS) is 0.00%
The market capitalization of Corvus Pharmaceuticals Inc (CRVS) is $443.38M
The stock symbol (or ticker) of Corvus Pharmaceuticals Inc is CRVS